|
CA2881554C
(en)
|
2012-08-22 |
2022-01-04 |
Cornell University |
Methods for inhibiting fascin
|
|
US20150203453A1
(en)
|
2012-10-02 |
2015-07-23 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
|
WO2014100463A1
(en)
|
2012-12-19 |
2014-06-26 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
|
ES2718495T3
(es)
|
2012-12-21 |
2019-07-02 |
Celgene Quanticel Res Inc |
Inhibidores de la histona desmetilasa
|
|
JP6514117B2
(ja)
|
2013-02-27 |
2019-05-15 |
エピセラピューティクス アーペーエス |
ヒストン脱メチル化酵素の阻害剤
|
|
EP2968282B1
(en)
|
2013-03-12 |
2018-05-09 |
Celgene Quanticel Research, Inc. |
Histone dementhylase inhibitors
|
|
CN105980386B
(zh)
|
2013-03-13 |
2021-08-13 |
基因泰克公司 |
吡唑并化合物及其用途
|
|
DK3107902T3
(da)
*
|
2014-02-20 |
2021-05-03 |
Cornell Univ Cornell Center For Technology Enterprise & Commercialization Cctec |
Forbindelser og fremgangsmåder til at hæmme fascin
|
|
SG11201610813TA
(en)
|
2014-06-25 |
2017-01-27 |
Quanticel Pharmaceuticals Inc |
Histone demethylase inhibitors
|
|
CA2957947A1
(en)
|
2014-08-27 |
2016-03-03 |
Gilead Sciences, Inc. |
Compounds and methods for inhibiting histone demethylases
|
|
AU2015317806A1
(en)
|
2014-09-17 |
2017-04-13 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
|
US10030017B2
(en)
|
2014-09-17 |
2018-07-24 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
|
US9758517B2
(en)
|
2014-09-17 |
2017-09-12 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
|
US10059687B2
(en)
|
2015-12-28 |
2018-08-28 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
|
CN105601555B
(zh)
*
|
2016-03-14 |
2018-07-31 |
苏州大学 |
一种制备硝基吲哚衍生物的方法
|
|
ES2921009T3
(es)
*
|
2016-03-15 |
2022-08-16 |
Celgene Quanticel Res Inc |
Inhibidores de desmetilasas de histonas
|
|
US10150754B2
(en)
*
|
2016-04-19 |
2018-12-11 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
|
MX2018014377A
(es)
|
2016-05-27 |
2019-03-14 |
Gilead Sciences Inc |
Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
PT3507276T
(pt)
|
2016-09-02 |
2022-01-11 |
Gilead Sciences Inc |
Compostos moduladores do recetor de tipo toll
|
|
MA46535A
(fr)
|
2016-10-14 |
2019-08-21 |
Prec Biosciences Inc |
Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
|
|
WO2018073828A1
(en)
*
|
2016-10-20 |
2018-04-26 |
B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University |
Dna primase and gyrase inhibitors
|
|
TWI714820B
(zh)
|
2017-01-31 |
2021-01-01 |
美商基利科學股份有限公司 |
替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
WO2018149986A1
(en)
*
|
2017-02-16 |
2018-08-23 |
Oryzon Genomics, S.A. |
2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
WO2019123339A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
SI3752501T1
(sl)
|
2018-02-13 |
2023-08-31 |
Gilead Sciences, Inc. |
Inhibitorji pd-1/pd-l1
|
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
|
|
EP3774883A1
(en)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
CA3093130C
(en)
|
2018-04-19 |
2023-10-17 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’－環二核苷酸
|
|
SI3820572T1
(sl)
|
2018-07-13 |
2023-12-29 |
Gilead Sciences, Inc. |
Inhibitorji pd-1/pd-l1
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
JP7158577B2
(ja)
|
2018-10-24 |
2022-10-21 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｐｄ－１／ｐｄ－ｌ１阻害剤
|
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
CA3117556A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
JP7350871B2
(ja)
|
2019-03-07 |
2023-09-26 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
２’３’－環状ジヌクレオチドおよびそのプロドラッグ
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
US20220257619A1
(en)
|
2019-07-18 |
2022-08-18 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
EP4017476A1
(en)
|
2019-08-19 |
2022-06-29 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
MY208114A
(en)
|
2019-09-30 |
2025-04-16 |
Gilead Sciences Inc |
Hbv vaccines and methods treating hbv
|
|
CN116057068A
(zh)
|
2019-12-06 |
2023-05-02 |
精密生物科学公司 |
对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
|
|
WO2021188959A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
BR112023002164A2
(pt)
|
2020-08-07 |
2023-03-14 |
Gilead Sciences Inc |
Profármacos de análogos de nucleotídeos de fosfonamida e seu uso farmacêutico
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
TW202348237A
(zh)
|
2021-05-13 |
2023-12-16 |
美商基利科學股份有限公司 |
TLR8調節化合物及抗HBV siRNA療法之組合
|
|
EP4359389A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2023386923A1
(en)
|
2022-11-21 |
2025-05-15 |
Nippon Shinyaku Co., Ltd. |
Compound serving as ddr1 kinase inhibitor, and medicine
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|